MedTrace Logo

A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout

NCT00741442 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-02-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether RDEA806 is effective in the treatment of hyperuricemia in gout patients.

Conditions

  • Hyperuricemia

Interventions

DRUG

RDEA806

Uricosuric agent for the treatment of gout

DRUG

Placebo

Matching Placebo.

Sponsors & Collaborators

  • Ardea Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Vijay Hingorani, MD, PhD, MBA · Ardea Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-04-30
Completion
2009-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741442 on ClinicalTrials.gov